Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors
- 23 June 2022
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 48 (6) , 101367
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based StudyGastroenterology, 2015
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015
- CKD and the Risk of Acute, Community-Acquired Infections Among Older People With Diabetes Mellitus: A Retrospective Cohort Study Using Electronic Health RecordsAmerican Journal of Kidney Diseases, 2015
- Excess Risk of Dying From Infectious Causes in Those With Type 1 and Type 2 DiabetesDiabetes Care, 2015
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese ratsEuropean Journal of Pharmacology, 2014
- Covariate Balancing Propensity ScoreJournal of the Royal Statistical Society Series B: Statistical Methodology, 2013
- Doubly Robust Estimation of Causal EffectsAmerican Journal of Epidemiology, 2011
- Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBaseDiabetes Care, 2011
- Diabetes and the Risk of Infection-Related Mortality in the U.S.Diabetes Care, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999